ADAR1 Capital Management’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
Other funds holding VTGN
ADAR1 Capital Management's VTGN Position: Q3 2026 in Review
ADAR1 Capital Management sold out of VistaGen Therapeutics (VTGN) in Q3 2026, closing a stake of 351,141 shares — an estimated $79.4K sold.
ADAR1 Capital Management first reported a position in VTGN in Q4 2023 and held it in 10 quarters. The position peaked at $1.26M in Q4 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.
- ADAR1 Capital Management reported no remaining VistaGen Therapeutics position as of Q3 2026 after selling out during the quarter.
- ADAR1 Capital Management sold 351,141 VistaGen Therapeutics shares in Q3 2026, an estimated $79.4K.
- ADAR1 Capital Management first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 10 quarters.
- ADAR1 Capital Management's VistaGen Therapeutics position peaked at $1.26M in Q4 2023.
- 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.
Based on ADAR1 Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.